Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02707965 · ClinicalTrials.gov registry record · Phase 1
Characterization of Epilepsy Patients BEEP 2b
A Phase 1 study, sponsored by Food and Drug Administration (FDA).
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT02707965 is a Phase 1 study that has completed, run by Food and Drug Administration (FDA). The registered enrollment target is 21 participants.
The verdict
NCT02707965, a Phase 1 study, has completed, sponsored by Food and Drug Administration (FDA).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
Some epilepsy patients are described as GB when they have worsened seizures or side effects related to switching between brand name and generic, or between generic antiepileptic drug (AED) products. In concert with Aim 1 (protocol BEEP2a), this study will uncover possible reasons for patient problems with the drug switching. Factors that will be studied in GB epilepsy patients include physiologic, psychological, and genetic factors, including in this protocol whether brand and generic AEDs are pharmacokinetically similar in GB individuals.
Interventions
- DRUG Oxcarbazepine (brand name vs generic drugs)
- DRUG Divalproex Sodium (brand name vs generic drugs)
- DRUG Carbamazepine (brand name vs generic drugs)
- DRUG Lamotrigine (brand name vs generic drugs)
- DRUG levetiracetam (brand name vs generic drugs)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2017-06-08 |
| Est. Completion | 2018-09-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02707965
The ClinicalTrials.gov registry entry for NCT02707965 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Food and Drug Administration (FDA), which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Oxcarbazepine (brand name vs generic drugs) is the first listed.
NCT02707965 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02707965 about?
NCT02707965 is a clinical study titled "Characterization of Epilepsy Patients BEEP 2b". Some epilepsy patients are described as GB when they have worsened seizures or side effects related to switching between brand name and generic, or between generic antiepileptic drug (AED) products. In concert with Aim 1 (protocol BEEP2a), this study will uncover possible reasons for patient problem...
What is the current status of trial NCT02707965?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2017-06-08. Estimated completion is 2018-09-04.
What interventions are being tested in trial NCT02707965?
The interventions under investigation include: Oxcarbazepine (brand name vs generic drugs) (DRUG), Divalproex Sodium (brand name vs generic drugs) (DRUG), Carbamazepine (brand name vs generic drugs) (DRUG), Lamotrigine (brand name vs generic drugs) (DRUG), levetiracetam (brand name vs generic drugs) (DRUG).
Who is sponsoring clinical trial NCT02707965?
This trial is sponsored by Food and Drug Administration (FDA), which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.